Therefore, we believe that repurposing 2-ME2 to downregulate RON could be developed as an approach for management of castrate resistant prostate cancer especially in blacks and other tumors that exhibit elevated activation of RON signaling. The gene discussed is MST1R; the disease is prostate cancer.